Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis

American Journal of Pathology

Volumn 161, Issue 4, 2002, Pages 1419-1427

  Romas, Evan ^a   Sims, Natalie A ^a   Hards, Daphne K ^b   Lindsay, Mandy ^c   Quinn, Julian W M ^b   Ryan, Peter F J ^c   Dunstan, Colin R ^d   Martin, T John ^b   Gillespie, Matthew T ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; HYBRID PROTEIN; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE DESTRUCTION; BONE EROSION; BONE MATRIX; CARTILAGE DEGENERATION; CELL COUNT; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCATION; IN SITU HYBRIDIZATION; INFLAMMATION; JOINT DESTRUCTION; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVITIS; T LYMPHOCYTE;

EID: 0036792512     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64417-3     Document Type: Article

References (46)

1. Goldring SR: The final pathogenetic steps in focal bone erosions in rheumatoid arthritis. Ann Rheum Dis 2000, 59(Suppl 1):i72-i74
2. Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, Nguyen T, Emery P: Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998, 25:1282-1289
3. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR: Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951
4. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM: OPGL is a key regulator of osteoclastogenesis, lymphocyte development, and lymph-node organogenesis. Nature 1999, 397:315-323
5. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176
6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319
7. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545
8. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97:1566-1571
9. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999, 145:527-538
10. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ: Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448
11. Yamamoto M, Murakami T, Nishikawa M, Tsuda E, Mochizuki S, Higashio K, Akatsu T, Motoyoshi K, Nagata N: Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 1998, 139:4012-4015
12. Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, Mao M, Kostenuik P, Dunstan CR, Lacey DL, Sheng JZ: Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 2001, 3:197-205
13. Bateman TA, Dunstan CR, Ferguson VL, Lacey DL, Ayers RA, Simske SJ: Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone 2000, 26:443-449
14. Bateman TA, Dunstan CR, Lacey DL, Ferguson VL, Ayers RA, Simske SJ: Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. J Orthop Res 2001, 19:518-523
15. Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR: Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000, 60:783-787
16. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW: Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain, and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000, 6:521-528
17. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61:4432-4436
18. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR: A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 1999, 14:1478-1485
19. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268
20. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309
21. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JMW, Ryan PFJ, Martin TJ, Gillespie MT: Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000, 43:821-826
22. Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillespie MT: Activated T cells support osteoclast formation in vitro. Biochem Biophys Res Commun 1999, 265:144-150
23. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250-258
24. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S: Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000, 43:2523-2530
25. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N: Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012
26. Takayanagi H, lizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S: Involvement of receptor activator of nuclear factorκB/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-269
27. Ross FP: RANKing the importance of measles virus in Paget's disease. J Clin Invest 2000, 105:555-558
28. Hanyu T, Chotanaphuti T, Arai K, Tanaka T, Takahashi HE: Histomorphometric assessment of bone changes in rats with type II collagen-induced arthritis. Bone 1999, 24:485-490
29. Bakharevski O, Stein-Oakley AN, Thomson NM, Ryan PFJ: Collagen-induced arthritis in rats: contrasting effect of subcutaneous versus intradermal inoculation of type II collagen. J Rheumatol 1998, 25:1945-1952
30. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D: Efficacy of sustained levels of interleukin-1 receptor antagonist in animal models of arthritis. Arthritits Rheum 1999, 43:498-506
31. Sims NA, White CP, Sunn KL, Thomas GP, Drummond ML, Morrison NA, Eisman JA, Gardiner EM: Human and murine osteocalcin gene expression: conserved tissue restricted expression and divergent responses to 1,25 dihydroxyvitamin D3 in vivo. Mol Endocrinol 1997, 11:1695-1708
32. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT: Localization of RANKL mRNA and protein in skeletal and extra-skeletal tissues. Bone 1999, 25:525-534
33. Myers LK, Rosloniec EF, Cremer MA, Kang AH: Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997, 61:1861-1872
34. Feige U, Campagnuolo G, Bolon B: Recombinant osteoprotegerin regulates osteoclast numbers in a schedule dependent manner in joints of male Lewis rats with adjuvant arthritis. Ann Rheum Dis 2001, 60(Suppl):Abstr OP0061
35. Anderson DM, Maraskovsky E, Billingsley WL Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179
36. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese E: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699
37. Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M: The osteoprotegerin/receptor activator of nuclear factor KB/receptor activator of nuclear factor κB ligand system in cartilage. Arthritis Rheum 2001, 44:2768-2776
38. Ikeda T, Utsuyama M, Hirokawa K: Expression profiles of receptor activator of nuclear factor κB ligand, receptor activator of nuclear factor κB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res 2000, 16:1416-1425
39. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352
40. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL: TNFα induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488
41. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Am Y: Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001, 276:563-568
42. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B: Anti-interleukine-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000, 57:1457-1470
43. Redlich K, Maier A, Hayer S, Kollias G, Dunstan CR, Lang S, Woloszczuk W, Steiner G, Smolen J, Schett G: Effect of osteoprotegerin and pamidronate treatment in transgenic mice overexpressing human TNFα. Ann Rheum Dis 2001, 60(Suppl):Abstr FRI0010
44. Feige U, Hu YL, Morony S, Campagnuolo G, Duryea D, Bolon B: Osteoclast numbers in joints of rats with adjuvant arthritis are decreased by treatment with IL-lra and/or pegulated sTNF-RI. Ann Rheum Dis 2001, 60(Suppl):Abstr OP0016
45. Lubberts E, Joosten LAB, Chabaud M, van den Bersselaer L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, van Den Berg WB: IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosions. J Clin Invest 2000, 105:1697-1710
46. Arend WP: Cytokines and cellular interactions in inflammatory arthritis. J Clin Invest 2001, 107:1081-1082